Literature DB >> 28904177

Limited proteolysis as a tool to probe the tertiary conformation of dysferlin and structural consequences of patient missense variant L344P.

Natalie Woolger1,2, Adam Bournazos1,2, Reece A Sophocleous1,2, Frances J Evesson1,2, Angela Lek1,2, Birgit Driemer1,2, R Bryan Sutton3, Sandra T Cooper4,2.   

Abstract

Dysferlin is a large transmembrane protein that plays a key role in cell membrane repair and underlies a recessive form of inherited muscular dystrophy. Dysferlinopathy is characterized by absence or marked reduction of dysferlin protein with 43% of reported pathogenic variants being missense variants that span the length of the dysferlin protein. The unique structure of dysferlin, with seven tandem C2 domains separated by linkers, suggests dysferlin may dynamically associate with phospholipid membranes in response to Ca2+ signaling. However, the overall conformation of the dysferlin protein is uncharacterized. To dissect the structural architecture of dysferlin, we have applied the method of limited proteolysis, which allows nonspecific digestion of unfolded peptides by trypsin. Using five antibodies spanning the dysferlin protein, we identified a highly reproducible jigsaw map of dysferlin fragments protected from digestion. Our data infer a modular architecture of four tertiary domains: 1) C2A, which is readily removed as a solo domain; 2) midregion C2B-C2C-Fer-DysF, commonly excised as an intact module, with subdigestion to different fragments suggesting several dynamic folding options; 3) C-terminal four-C2 domain module; and 4) calpain-cleaved mini-dysferlinC72, which is particularly resistant to proteolysis. Importantly, we reveal a patient missense variant, L344P, that largely escapes proteasomal surveillance and shows subtle but clear changes in tertiary conformation. Accompanying evidence from immunohistochemistry and flow cytometry using antibodies with conformationally sensitive epitopes supports proteolysis data. Collectively, we provide insight into the structural topology of dysferlin and show how a single missense mutation within dysferlin can exert local changes in tertiary conformation.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  conformational change; dysferlin; patient missense variant; protein conformation; protein domain; proteolysis; tertiary structure

Mesh:

Substances:

Year:  2017        PMID: 28904177      PMCID: PMC5682967          DOI: 10.1074/jbc.M117.790014

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Probing protein structure by limited proteolysis.

Authors:  Angelo Fontana; Patrizia Polverino de Laureto; Barbara Spolaore; Erica Frare; Paola Picotti; Marcello Zambonin
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

Review 2.  Ferlins: regulators of vesicle fusion for auditory neurotransmission, receptor trafficking and membrane repair.

Authors:  Angela Lek; Frances J Evesson; R Bryan Sutton; Kathryn N North; Sandra T Cooper
Journal:  Traffic       Date:  2011-09-06       Impact factor: 6.215

Review 3.  Membrane Repair: Mechanisms and Pathophysiology.

Authors:  Sandra T Cooper; Paul L McNeil
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

4.  CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.

Authors:  Xi Yin; Qian Wang; Ting Chen; Junwei Niu; Rui Ban; Jiexiao Liu; Yanling Mao; Chuanqiang Pu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients.

Authors:  W H Linssen; N C Notermans; Y Van der Graaf; J H Wokke; P A Van Doorn; C J Höweler; H F Busch; A E De Jager; M De Visser
Journal:  Brain       Date:  1997-11       Impact factor: 13.501

6.  Novel protein domains and repeats in Drosophila melanogaster: insights into structure, function, and evolution.

Authors:  C P Ponting; R Mott; P Bork; R R Copley
Journal:  Genome Res       Date:  2001-12       Impact factor: 9.043

7.  The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding.

Authors:  C von Poser; K Ichtchenko; X Shao; J Rizo; T C Südhof
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

8.  Quantitation of the calcium and membrane binding properties of the C2 domains of dysferlin.

Authors:  Nazish Abdullah; Murugesh Padmanarayana; Naomi J Marty; Colin P Johnson
Journal:  Biophys J       Date:  2014-01-21       Impact factor: 4.033

9.  Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy.

Authors:  J Liu; M Aoki; I Illa; C Wu; M Fardeau; C Angelini; C Serrano; J A Urtizberea; F Hentati; M B Hamida; S Bohlega; E J Culper; A A Amato; K Bossie; J Oeltjen; K Bejaoui; D McKenna-Yasek; B A Hosler; E Schurr; K Arahata; P J de Jong; R H Brown
Journal:  Nat Genet       Date:  1998-09       Impact factor: 38.330

10.  Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.

Authors:  Eduard Gallardo; Noemi de Luna; Jordi Diaz-Manera; Ricardo Rojas-García; Lidia Gonzalez-Quereda; Bàrbara Flix; Antoine de Morrée; Silvère van der Maarel; Isabel Illa
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

View more
  2 in total

1.  Owning, not doing: my transition from master's to PhD student.

Authors:  Yuning Wang
Journal:  Nature       Date:  2022-01-18       Impact factor: 49.962

2.  Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes.

Authors:  Esther Fernández-Simón; Cinta Lleixà; Xavier Suarez-Calvet; Jordi Diaz-Manera; Isabel Illa; Eduard Gallardo; Noemí de Luna
Journal:  BMC Musculoskelet Disord       Date:  2020-11-27       Impact factor: 2.362

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.